OKYO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

OK

Mkt Cap

$73.8M

Volume

25.61K

Loading chart

OK

OKYOOKYO Pharma Limited Ordinary Shares

OKYO

Pay with—

Available Balance0.00

OK

Mkt Cap

$75.0M

Volume

25.61K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 PlansOKYO Pharma filed its annual report for fiscal year ended March 31, 2026, announcing a strengthened cash position of $20.6 million following a $22 million capital raise in February 2026. The company is fully funded to complete its NEPTUNE Phase 3 pivotal trial for urcosimod in neuropathic corneal pain, with trial initiation planned for the second half of 2026. The trial will enroll approximately 111 patients and is designed as a potential single-trial registration pathway supported by positive FDA feedback.GlobeNewswire Inc. · Jul 20, 2026

OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual MeetingOKYO Pharma will present Phase 2 clinical data for urcosimod, its lead candidate for neuropathic corneal pain treatment, at the ASCRS Annual Meeting in Washington, DC on April 11, 2026. The company will also hold a Scientific Advisory Board meeting with leading ophthalmology experts to review data and guide the upcoming Phase 2b/3 trial planned for the first half of 2026. Urcosimod has received FDA Fast Track designation and showed positive efficacy and safety results in the Phase 2 study.GlobeNewswire Inc. · Apr 7, 2026

OKYO Pharma Announces Chief Development Officer and Director Acquires SharesOKYO Pharma Limited announced that Chief Development Officer Gary Jacob acquired 30,980 ordinary shares at $1.59 per share. The company is advancing its flagship drug urcosimod, a ChemR23 agonist, following positive Phase 2a data in neuropathic corneal pain patients. OKYO plans to initiate a Phase 2b/3 trial with approximately 150 subjects in the first half of 2026.GlobeNewswire Inc. · Mar 19, 2026

OKYO Abstract Selected for Presentation at Premier Global Ophthalmology CongressOKYO Pharma announced that its abstract for urcosimod, a novel non-opioid eye-drop therapy for neuropathic corneal pain (NCP), has been accepted for presentation at the ARVO 2026 Annual Meeting in Denver. The Phase 2a clinical trial demonstrated clinically meaningful pain reduction and quality-of-life improvements in NCP patients, with potential to restore corneal nerve structure. The company plans to initiate a larger Phase 2b/3 trial with approximately 150 patients in the first half of 2026.GlobeNewswire Inc. · Feb 23, 2026

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary SharesOKYO Pharma Limited announced a public offering of 10.8 million ordinary shares at $1.85 per share, expected to raise approximately $20 million in gross proceeds (up to $23 million with underwriter option). The company plans to use proceeds for clinical development of its product candidates, including a Phase 2b/3 trial of its flagship drug urcosimod for neuropathic corneal pain. Piper Sandler & Co. is serving as sole manager, with closing expected on February 17, 2026.GlobeNewswire Inc. · Feb 13, 2026

OKYO Pharma Announces Public Offering of Ordinary SharesOKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company, announced an underwritten public offering of ordinary shares with Piper Sandler & Co. as the sole book-running manager. The company plans to use net proceeds for clinical development of its neuropathic corneal pain and inflammatory eye disease therapies, including a planned Phase 2b/3 trial of its flagship drug urcosimod.Benzinga · Feb 12, 2026

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal PainOKYO Pharma plans to accelerate the clinical development of urcosimod, its drug candidate for treating neuropathic corneal pain, by analyzing data from an early closure of its Phase 2 trial. The company aims to meet with the FDA to discuss further development of urcosimod.GlobeNewswire Inc. · Apr 30, 2025

OKYO Pharma Announces Chairman and CEO Acquire SharesOKYO Pharma Limited, a clinical-stage biopharmaceutical company, announced that its CEO and Executive Chairman have purchased a total of 30,000 shares of the company's ordinary shares on NASDAQ at a price of US$1.04 per share.GlobeNewswire Inc. · Jan 31, 2025

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal PainOKYO Pharma has dosed the first patient in a Phase 2 clinical trial of its drug candidate OK-101 to treat neuropathic corneal pain, a condition with no FDA-approved treatments. The trial is designed to evaluate the safety and efficacy of OK-101 in 48 patients with neuropathic corneal pain.GlobeNewswire Inc. · Oct 23, 2024

OKYO Pharma CEO Interview to Air on Bloomberg TVOKYO Pharma, a clinical-stage biopharmaceutical company, announced that its CEO, Dr. Gary S. Jacob, will be interviewed on Bloomberg TV. The company is developing therapies for dry eye disease and neuropathic corneal pain, with its lead candidate OK-101 showing promising results in a recent Phase 2 trial.GlobeNewswire Inc. · Aug 23, 2024

to start trading

OK

OKYOOKYO Pharma Limited Ordinary Shares

OKYO

Pay with—

Available Balance0.00

Your PositionYou don't own any OKYO yet.

Related Tickers

Earnings